目的 探討?zhàn)鲅阅z囊聯(lián)合艾瑞昔布片治療膝骨關(guān)節(jié)炎的臨床療效。方法 選取2020年3月—2022年3月中國人民解放軍聯(lián)勤保障部隊第九〇四醫(yī)院收治的130例膝骨關(guān)節(jié)炎患者，根據(jù)隨機數(shù)字表法將所有患者分為對照組和治療組，每組各65例。對照組餐后溫水送服艾瑞昔布片，1片/次，2次/d。治療組在對照組基礎(chǔ)上口服瘀血痹膠囊，6粒/次，3次/d。兩組患者連續(xù)用藥8周。觀察兩組患者的臨床療效，采用視覺模擬評分法（VAS）評估兩組患者的疼痛程度，采用改良版西安大略和麥克馬斯特大學(xué)骨關(guān)節(jié)炎指數(shù)量表（WOMAC）評估兩組患者的膝關(guān)節(jié)功能，比較兩組患者治療前后血清炎癥因子白介素-1β（IL-1β）、白細胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、C反應(yīng)蛋白（CRP）水平。結(jié)果 治療后，治療組總有效率（95.38%）高于對照組（84.62%），差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組VAS、WOMAC評分均顯著下降（P<0.05），且治療組VAS、WOMAC評分均明顯低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組血清IL-1β、IL-6、TNF-α、CRP水平均顯著下降（P<0.05），且治療組血清IL-1β、IL-6、TNF-α、CRP水平低于對照組，差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 瘀血痹膠囊聯(lián)合艾瑞昔布片治療膝骨關(guān)節(jié)炎具有較好的臨床療效，可有效緩解患者疼痛程度，改善膝關(guān)節(jié)功能，減輕炎癥反應(yīng)，且安全性較好。

Objective To investigate the clinical efficacy of Yuxuebi Capsules combined with Imrecoxib Tablets in treatment of knee osteoarthritis. Methods Patients (130 cases) with knee osteoarthritis in the 904th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army from March 2020 to March 2022 were divided into control and treatment groups according to the random number table method, and each group had 65 cases. Patients in the control group were po administered with Imrecoxib Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Yuxuebi Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the VAS was used to evaluate the pain degree of two groups of patients, and the WOMAC was used to evaluate the knee joint function of two groups of patients. The serum levels of inflammatory factors (IL-1β, IL-6, TNF-α, and CRP) before and after treatment in two groups were compared. Results After treatment, the total effective rate of the treatment group (95.38%) was higher than that of the control group (84.62%), and the difference was statistically significant (P < 0.05). After treatment, the VAS scores and WOMAC scores of two groups were significantly decreased (P < 0.05), and the VAS score and WOMAC score of the treatment group were significantly lower than those of the control group, the difference was statistically significant (P < 0.05). After treatment, the serum levels of IL-1β, IL-6,TNF-α, and CRP in two groups were significantly decreased (P < 0.05), and the serum levels of IL-1β, IL-6, TNF-α, and CRP in the treatment group were lower than those in the control group, and the difference was statistically significant (P< 0.05). Conclusion Yuxuebi Capsules combined with Imrecoxib Tablets has clinical curative effect in treatment of knee osteoarthritis, which can effectively relieve pain, improve knee joint function, and reduce inflammation reaction, with good safety.

R982

太倉市科技計劃項目（TC2020JCYL06）